UNSPSC 51292904: Desipramine

This classification denotes a tricyclic antidepressant with the molecular formula C18H22N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TG537D343B, chemically known as 10,11-dihydro-5-(3-methylaminopropyl)-5h-dibenz(b,f)azepine but generally known as desipramine, which bears US NIH Compound Identifier 2995. European Medicines Agency schedules Desipramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06995MIG.

UNSPSC 51292904 Desipramine, a Commodity code, nominally covers a specific tricyclic antidepressant drug product; however, recent state and local opportunities tagged under this code reveal that buyers are actually procuring pharmaceuticals and related health products across a much broader scope — generic multi-source drugs, over-the-counter products, naloxone, and drug deactivation systems. State and local health agencies, cooperative purchasing alliances, and county health departments are the primary issuing bodies. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities, including Oregon, with proposals due March 26, 2026. Seminole County, Florida solicited naloxone and safe drug deactivation systems through an IFB released in June 2026 with a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted a Request for Information in April 2026 to explore direct-to-manufacturer prescription programs and vendor capabilities for pharmacy benefit management outside traditional pharmacy benefit manager and group purchasing organization channels.

Recent activity concentrates in the Midwest and South, with solicitations from Minnesota (through MMCAP's multistate cooperative), Texas, and Florida. MMCAP's RFP requires vendors to maintain relationships with authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson, with products to be available by May 15, 2026, and contracts effective July 1, 2026 for an initial two-year term. Pricing evaluation is weighted heavily on price competitiveness (75 percent), with vendors required to certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act. Seminole County's naloxone procurement requires quarterly deliveries of 1,900 units of naloxone and 800 safe drug deactivation systems annually to the Seminole County Community Health Building, with a two-year initial term and optional one-year renewal, and bidders must demonstrate E-Verify compliance and workers' compensation and commercial general liability insurance. The Texas RFI signals exploratory state-level interest in reshaping pharmacy benefit contracting strategies but has not yet moved to formal competitive procurement.